VacZine Analytics  
ExpertREACT - PREMIUM

Prevnar and PCV-13 versus Synflorix - waging war at 27th ESPID, Brussels with antibody levels.

Published 23rd June 2009

At the recent European Society For Pediatric Infectious Diseases, (ESPID) 2009 held in Brussels, it was clear that the battle between Wyeth's Prevnar franchise and GSK's newly licensed pneumococcal vaccine, SynflorixTM had reached a new level of intensity. VacZine Analytics diagnoses each company marketing strategy in pneumococcal vaccines and current reaction.

PAGES: 2

PREMIUMThis article is available only to selected VacZine Analytics clients or can be purchased for delivery.

CAT No: CONTENTS: PRICE*: PURCHASE:
VAER090623 Click here>> USD $14.99 GBP 9.99
*Price quote is for global license. For UK orders VAT will be added at 15.0%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this article?






© 2009 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains